Ocrelizumab is a humanized monoclonal antibody that is directed against CD20-expressing B-cells. CD20 is a cell surface antigen that is present on pre-B and mature B lymphocytes. Ocrelizumab binds to CD20 on B lymphocytes and causes antibody-dependent cellular cytolysis and complement-mediated lysis. <a id="
Localización de Nuestra Oficina principal:
Dirección Física:
1441 F.D. Roosevelt Ave.
San Juan, P.R. 00936
Dirección Postal:
P.O. Box 363628
San Juan, P.R. 00936-3628